Cancer Family
Malignant Skin Neoplasm
CI-CAN-00000250Explore in graph →
320 active trials14 approved drugs64 evidence items
- NCIt
- C2920
Loading cancer entity…
Cancer Family
CI-CAN-00000250Explore in graph →
Clinical trials
1,248 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (202)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03906253 | Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia | recruiting | N/A | 72 | Wright State UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04122456 | DNA Repair Activity in the Skin of Day and Night Shift Workers | recruiting | N/A | 48 | Wright State UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06207812 |
| Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis |
| recruiting |
| — |
| 100 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Jul 16, 2026 |
| clinicaltrials |
| NCT06428721 | The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population | recruiting | N/A | 80 | Wright State UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06662058 | Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation | recruiting | N/A | 118 | Emory UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06615635 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients(DaRT) | recruiting | N/A | 28 | Alpha Tau Medical LTD.INDUSTRY | 2 | Jul 15, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06698822 | A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA | recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06288191 | Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma | recruiting | Phase 2 | 20 | Melanoma Institute AustraliaOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07680699 | NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma(NEOSENT) | recruiting | — | 250 | AC Camargo Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04256018 | Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome | recruiting | Phase 2 | 30 | Stanford UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06508463 | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma | recruiting | Phase 1 | 21 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06860880 | Combating Cancer-Related Fatigue: A Personalized Supportive Care Program | recruiting | N/A | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07049276 | The Multicentre Selective Lymphadenectomy Trial - 3(MSLT-3) | recruiting | N/A | 1,500 | Melanoma Institute AustraliaOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT07327489 | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)(ELEPHAS-05) | recruiting | — | 2,000 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07670858 | Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC) | recruiting | Phase 1 | 48 | Feldan TherapeuticsINDUSTRY | 2 | Jun 29, 2026 | clinicaltrials |
| NCT07094685 | Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer(SENIOR-HN) | recruiting | Phase 2 | 28 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04975152 | Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma | recruiting | Phase 1 | 36 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07215988 | Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study | recruiting | — | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07354152 | COmparison of the Use of a PERforator Flap Versus Total Skin GRAft in the Management of Loss of Substance After Resection of Cutaneous Melanoma - Pilot Study(COPERGRAM1) | recruiting | — | 40 | Nantes University HospitalOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07406022 | Optical Characterization and Multi-modality, Multi-scale Modeling of Human Skin Applied to Cancer Diagnosis.(OpticSkin) | recruiting | — | 140 | Centre Hospitalier Régional Metz-ThionvilleOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07201012 | Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome(SMT-SL) | recruiting | N/A | 150 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06971848 | Evaluation of Skin Tests in Biotherapy Allergies(ETCABIO) | recruiting | N/A | 70 | University Hospital, AngersOTHER_GOV | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05475925 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | recruiting | Phase 1 / Phase 2 | 200 | Dren BioINDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT04068155 | Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors | recruiting | N/A | 80 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04534127 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia | recruiting | N/A | 56 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06967961 | Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers(DP-PAN-CANCER) | recruiting | N/A | 450 | Institut Claudius RegaudOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07266142 | Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker | recruiting | — | 7,500 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 40 | Memgen, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06567314 | Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma | recruiting | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | recruiting | Phase 1 / Phase 2 | 336 | IDEAYA BiosciencesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT07286318 | A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients | recruiting | Early Phase 1 | 20 | Marissa LoblOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06319196 | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma(ClearMe) | recruiting | Phase 2 | 54 | University Health Network, TorontoOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627698 | Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma(DUET-MEL) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT06998342 | MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer(MOHSAHRTSS) | recruiting | Phase 2 | 24 | University of Vermont Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07606508 | Follow-up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment.(CAREPI) | recruiting | — | 1,500 | University Hospital, LilleOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06489301 | Mechanisms for Laser-Induced Rejuvenation | recruiting | N/A | 12 | Wright State UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07330323 | CARES : Customized Aftercare Report for Evaluated Skin Cancer Patients(CARES) | recruiting | N/A | 150 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05978141 | A Registry for People With T-cell Lymphoma | recruiting | — | 1,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06992427 | High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer(HOPE) | recruiting | Phase 3 | 228 | Alliance for Clinical Trials in OncologyOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05747625 | (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 60 | Eben RosenthalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06384924 | Raman Spectroscopy and Skin Cancer | recruiting | — | 20 | Tiezhi ZhangOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT03713203 | PAGETEX® Photodynamic Therapy Device for the Treatment of Extra Mammary Paget's Disease of the Vulva (EMPV).(PAGETEX) | recruiting | N/A | 24 | University Hospital, LilleOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04778449 | Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma | recruiting | — | 5,000 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05956041 | Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | recruiting | Phase 2 | 23 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 17, 2026source: clinicaltrials